Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Multiple Massachusetts-based vaccine companies, including Moderna, are affected by U.S. Health and Human Services Secretary ...

“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...

Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...

Moderna Inc. (NASDAQ: MRNA) has announced plans to reduce its global workforce by approximately 10% by the end of the year due to decreasing COVID-19 vaccine sales and market uncertainty.

RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...

HHS Secretary Robert F. Kennedy Jr. says the federal government is calling off around $500 million worth of vaccine ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...